Company: PRTA
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001559053-25-000017
Chunk: 65

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 65
---
 At the Committee's instruction, Pay

Governance used criteria based on (a) industry sector, stage of development and geography (biotechnology companies in Phase 1 to 3 of clinical development, and companies located in the San Francisco, California area or other biotechnology hub markets that reflect Prothena's talent market), (b) market capitalization between $1.0 billion and $10.0 billion (based on the Company’s then-market capitalization of approximately $3.0 billion), and (c) number of employees (generally under 500 employees). These criteria were used to develop a recommended list of peer companies, with respect to fiscal year 2024, which Pay Governance presented to the Committee. As a result of this analysis, ACADIA Pharmaceuticals, Axsome, Biohaven Ltd., Cerevel Therapeutics, Intra-Cellular, Sage Therapeutics, and Xenon Pharmaceuticals were added to our peer group; AnaptsysBio, ImmunoGen, Iovance Biotherapeutics, Kodiak Sciences, Krystal Biotech, Kura Oncology, Mersana Therapeutics, NGM Biopharmaceuticals, and Sangamo Therapeutics were removed from our peer group. The peer group companies identified by Pay Governance and considered, discussed, and approved by the Committee to assist the Committee in its evaluation of 2024 compensation decisions were:

| ACADIA Pharm.        
 Alector              
 Anavex Life Sciences 
 Arcus Biosciences    
 Arrowhead Pharm.     
 Axsome               
 Biohaven Ltd.        
 Celldex Therapeutics 
 Cerevel Therapeutics |     | Crinetics Pharm.    
 Cytokinetics        
 Denali Therapeutics 
 Intra-Cellular      
 Karuna Therapeutics 
 Replimune Group     
 Sage Therapeutics   
 Xenon Pharm.        |

For competitive assessment purposes, Pay Governance used executive compensation data publicly reported by these peer group companies ( i.e ., proxy statement data), as well as survey data from other publicly-traded pre-commercial biotechnology companies with characteristics ( e.g. , market capitalization, stage of development, and number of

| 2025 PROXY STATEMENT |     | 39 |

TABLE OF CONTENTS

| COMPENSATION DISCUSSION AND ANALYSIS |

employees) deemed comparable to these peer group companies and the Company.

Pay Governance’s reports to the Committee included a review of our existing executive compensation programs, practices, levels, and arrangements; each executive officer’s compensation relative to the market data